Sunday, April 27, 2025 4/27/2025

Improving marginal allograft outcomes through cell junction stabilization in transplantation

Award Number: R44DK125244
ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By:

View Award Description

Improving marginal allograft outcomes through cell junction stabilization in transplantation - Project Summary/Abstract: Transplantation is a highly successful therapy for end-stage renal disease but there is a significant shortage of available donor organs that has forced utilization of low-quality kidneys to save patient’s lives. Extending the donor criteria has coincided with a growing appreciate that factors associated with organ donation, procurement and storage greatly affect post-transplantation outcomes. Unlike heart transplantation, kidney donors can be derived from a variety of sources that include living donors, donation after brain death, and donation after cardiac death. However, the vast majority of kidneys are donated from deceased donors and donation after brain death or after cardiac death predispose poorer post-transplantation outcomes. Problems inherent to organ transplantation, such as ischemia and extended cold storage, also negatively affect and cause irreparable damage to the donor kidney. These injurious events are known to elicit endothelial cell (EC) dysfunction, inflammation, and organ injury that are further exacerbated upon implantation by ischemia reperfusion injury (IRI) while also priming the donor organ for alloimmune recognition. While cold preservation has greatly facilitated the use of cadaveric kidneys for transplantation by slowing metabolism to prevent cell death, current formulations do not minimize organ injury associated with cold storage or ischemia reperfusion injury. Vascular endothelum, which serves as a dynamic interface between the allograft and the recipient, is the initial target of the deleterious events that adversely affect graft health and function. Since gap and tight junctions regulate EC functionality, therapeutic strategies that promote the molecular and cellular integrity of endothelium of donor kidneys could preclude the mechanisms responsible for allograft damage and failure. FirstString Research Inc. has identified, characterized, and clinically-evaluated a novel peptide mimetic of connexin43, alpha-Connexin Carboxy-Terminal (aCT1), that stabilizes the gap and tight junctions of ECs during wound healing processes, leading to coordination of cellular communication, dampened inflammatory responses, reduced immune cell infiltrate, and enhanced regenerative properties. aCT1’s small, stable, soluble design facilitates direct translocation into cells for intracellular drug delivery. Preliminary studies in clinically relevant models of kidney, heart, and lung transplantation reveal that aCT1 supplementation to standard-of-care organ preservation solutions stabilizes cellular junctions to protect EC from injurious effects of IRI and extending cold storage time. We hypothesize that cold preservation induces cell junction damage, which leads to EC dysfunction, inflammation, and renal damage upon reperfusion, and that supplementation of the therapeutic aCT1 peptide to standard of care preservation solution will preserve cell junctions, thereby improving renal health and function leading to superior post-transplantation outcomes. Here we propose to investigate the effect of ex vivo aCT1 pretreatment on donor kidney function, inflammatory state, and tissue injury using clinically relevant pig kidney transplantation models and low-quality human kidneys.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = -$392,199 )
2024	2022	XEQUEL BIO, INC.	777 TAYLOR ST STE 1140	FORT WORTH	TX	76102	TARRANT	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	001	3	7/15/2024	NON-COMPETING CONTINUATION	-$392,199
2024	2022	XEQUEL BIO, INC.	1501 BELLE ISLE AVE STE 220	MOUNT PLEASANT	SC	29464	CHARLESTON	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	3	4/10/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = -$392,199

Issue Date FY: 2022 ( Subtotal = $987,481 )
2022	2022	XEQUEL BIO, INC.	1501 BELLE ISLE AVE STE 220	MOUNT PLEASANT	SC	29464	CHARLESTON	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	006	3	9/7/2022	NON-COMPETING CONTINUATION	$987,481
2022	2021	XEQUEL BIO, INC.	1501 BELLE ISLE AVE STE 220	MOUNT PLEASANT	SC	29464	CHARLESTON	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	002	2	3/22/2022	EXTENSION WITH OR WITHOUT FUNDS	$225,000
2022	2021	FIRSTSTRING RESEARCH, INC	300 WEST COLEMAN BOULEVARD SUITE 203	MOUNT PLEASANT	SC	29464	CHARLESTON	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	2	12/8/2021	EXTENSION WITH OR WITHOUT FUNDS	$0
2022	2021	XEQUEL BIO, INC.	1501 BELLE ISLE AVE STE 220	MOUNT PLEASANT	SC	29464	CHARLESTON	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	004	2	3/23/2022	EXTENSION WITH OR WITHOUT FUNDS	-$225,000
2022	2020	XEQUEL BIO, INC.	1501 BELLE ISLE AVE STE 220	MOUNT PLEASANT	SC	29464	CHARLESTON	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	005	1	6/10/2022	NEW	$0
2022	2020	XEQUEL BIO, INC.	1501 BELLE ISLE AVE STE 220	MOUNT PLEASANT	SC	29464	CHARLESTON	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	003	1	3/23/2022	NEW	$225,000
2022	2020	XEQUEL BIO, INC.	1501 BELLE ISLE AVE STE 220	MOUNT PLEASANT	SC	29464	CHARLESTON	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	001	1	3/22/2022	NEW	-$225,000
														Subtotal = $987,481

Issue Date FY: 2021 ( Subtotal = $993,803 )
2021	2021	FIRSTSTRING RESEARCH, INC	300 WEST COLEMAN BOULEVARD SUITE 203	MOUNT PLEASANT	SC	29464	CHARLESTON	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	2	6/23/2021	EXTENSION WITH OR WITHOUT FUNDS	$993,803
														Subtotal = $993,803

Issue Date FY: 2020 ( Subtotal = $300,000 )
2020	2020	FIRSTSTRING RESEARCH, INC	300 WEST COLEMAN BOULEVARD SUITE 203	MOUNT PLEASANT	SC	29464	CHARLESTON	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	1	4/15/2020	NEW	$300,000
														Subtotal = $300,000

Grand Total All Awards = $1,889,085

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Improving marginal allograft outcomes through cell junction stabilization in transplantation

Award Number: R44DK125244

ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer